X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs GLENMARK PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB GLENMARK PHARMA DR. REDDYS LAB/
GLENMARK PHARMA
 
P/E (TTM) x 27.3 13.9 196.7% View Chart
P/BV x 2.8 3.9 72.3% View Chart
Dividend Yield % 1.0 0.3 308.1%  

Financials

 DR. REDDYS LAB   GLENMARK PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-16
GLENMARK PHARMA
Mar-16
DR. REDDYS LAB/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs4,3831,262 347.3%   
Low Rs2,750672 409.5%   
Sales per share (Unadj.) Rs920.1270.6 340.1%  
Earnings per share (Unadj.) Rs126.124.9 506.9%  
Cash flow per share (Unadj.) Rs183.034.4 531.7%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %0.60.2 271.1%  
Book value per share (Unadj.) Rs685.8151.3 453.2%  
Shares outstanding (eoy) m170.61282.16 60.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.93.6 108.5%   
Avg P/E ratio x28.338.9 72.8%  
P/CF ratio (eoy) x19.528.1 69.4%  
Price / Book Value ratio x5.26.4 81.4%  
Dividend payout %15.98.0 197.3%   
Avg Mkt Cap Rs m608,481272,778 223.1%   
No. of employees `00021.710.0 216.1%   
Total wages/salary Rs m31,87413,782 231.3%   
Avg. sales/employee Rs Th7,244.47,614.9 95.1%   
Avg. wages/employee Rs Th1,470.91,374.8 107.0%   
Avg. net profit/employee Rs Th992.8700.2 141.8%   
INCOME DATA
Net Sales Rs m156,97876,340 205.6%  
Other income Rs m2,693356 756.0%   
Total revenues Rs m159,67176,696 208.2%   
Gross profit Rs m34,58714,172 244.1%  
Depreciation Rs m9,7052,691 360.6%   
Interest Rs m8241,789 46.1%   
Profit before tax Rs m26,75110,048 266.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,2373,028 172.9%   
Profit after tax Rs m21,5147,019 306.5%  
Gross profit margin %22.018.6 118.7%  
Effective tax rate %19.630.1 65.0%   
Net profit margin %13.79.2 149.1%  
BALANCE SHEET DATA
Current assets Rs m118,20159,096 200.0%   
Current liabilities Rs m68,36840,018 170.8%   
Net working cap to sales %31.725.0 127.0%  
Current ratio x1.71.5 117.1%  
Inventory Days Days6075 80.0%  
Debtors Days Days97119 81.3%  
Net fixed assets Rs m72,26539,075 184.9%   
Share capital Rs m853282 302.3%   
"Free" reserves Rs m111,54830,281 368.4%   
Net worth Rs m117,00942,703 274.0%   
Long term debt Rs m10,69024,873 43.0%   
Total assets Rs m200,104111,026 180.2%  
Interest coverage x33.56.6 505.8%   
Debt to equity ratio x0.10.6 15.7%  
Sales to assets ratio x0.80.7 114.1%   
Return on assets %11.27.9 140.7%  
Return on equity %18.416.4 111.9%  
Return on capital %21.617.5 123.3%  
Exports to sales %46.343.3 106.9%   
Imports to sales %9.07.4 120.5%   
Exports (fob) Rs m72,61833,044 219.8%   
Imports (cif) Rs m14,0505,672 247.7%   
Fx inflow Rs m75,40536,945 204.1%   
Fx outflow Rs m27,11561,066 44.4%   
Net fx Rs m48,290-24,122 -200.2%   
CASH FLOW
From Operations Rs m40,4763,449 1,173.7%  
From Investments Rs m-19,421-8,802 220.7%  
From Financial Activity Rs m-17,0096,986 -243.5%  
Net Cashflow Rs m4,046934 433.3%  

Share Holding

Indian Promoters % 25.5 48.3 52.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 6.9 78.3%  
FIIs % 35.3 34.4 102.6%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.5 145.7%  
Shareholders   75,885 56,727 133.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   WYETH LTD  IPCA LABS  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare DR. REDDYS LAB With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 18, 2017 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS